Biolyst › FATEFATE THERAPEUTICS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 19.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 19 concluded trials, 37% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
November 13, 2026 est.
Next quarterly earnings (projected) Earnings
—
September 30, 2027
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Trial Milestone
Phase 1
January 15, 2028
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors Trial Milestone
Phase 1
October 15, 2028
FT839 in Autoimmune Diseases Trial Milestone
Phase 1/Phase 2
May 1, 2029
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors Trial Milestone
Phase 1
July 1, 2029
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis Trial Milestone
Phase 2
Track FATE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open FATE in the tracker
Recent history
Date Event Type Phase
September 28, 2026
8-K filed: Other event Filing
—
August 13, 2026
Quarterly results filed (8-K) Earnings
—
June 15, 2026
8-K filed: Leadership change Corporate
—
June 4, 2026
8-K filed: Other event Filing
—
May 13, 2026
Quarterly results filed (8-K) Earnings
—
February 26, 2026
Quarterly results filed (8-K) Earnings
—
November 13, 2025
Quarterly results filed (8-K) Earnings
—
October 27, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
October 14, 2025
8-K filed: Leadership change, Reg FD disclosure Corporate
—
August 12, 2025
Quarterly results filed (8-K) Earnings
—
June 18, 2025
FT819 in Subjects With B-cell Malignancies Trial Milestone
Phase 1
June 6, 2025
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) Trial Milestone
Phase 1
May 30, 2025
8-K filed: Leadership change, Reg FD disclosure Corporate
—
May 13, 2025
Quarterly results filed (8-K) Earnings
—
September 20, 2024
FT576 in Subjects With Multiple Myeloma Trial Milestone
Phase 1
October 23, 2023
FT516 in Subjects With Advanced Hematologic Malignancies Trial Milestone
Phase 1
September 27, 2023
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies Trial Milestone
Phase 1
August 11, 2023
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Trial Milestone
Phase 1
August 11, 2023
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Trial Milestone
Phase 1
August 11, 2023
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors Trial Milestone
Phase 1
July 13, 2023
FT538 in Subjects With Advanced Hematologic Malignancies Trial Milestone
Phase 1
November 15, 2022
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors Trial Milestone
Phase 1
December 4, 2020
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Trial Milestone
Phase 1/Phase 2
May 29, 2020
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Trial Milestone
Phase 1
December 15, 2016
A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders Trial Milestone
Phase 1
December 15, 2016
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies Trial Milestone
Phase 1
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.